User:Mac/Agenda: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
Line 21: Line 21:
* [[Mac/Agenda/2-Dec-2009#Reference_Labs_market_data|Get Annual Reports from key companies listed; summarize]]
* [[Mac/Agenda/2-Dec-2009#Reference_Labs_market_data|Get Annual Reports from key companies listed; summarize]]
* Add papers about [[Diagnostic_Kits/Commons_based_cases_in_Kits#GDx_Reference_Materials | GDx reference materials from Journal of Molecular Diagnostics]]
* Add papers about [[Diagnostic_Kits/Commons_based_cases_in_Kits#GDx_Reference_Materials | GDx reference materials from Journal of Molecular Diagnostics]]
* add profiles of major Personal Genomics companies to [[Diagnostic_Kits/Give_an_overall_picture_of_the_Kits'_sector#major_companies_in_Personal_Genomics_industry | Overall Picture of Kits Sector]]


</strike>
</strike>

Revision as of 17:25, 19 January 2010

18 Jan 2010

Notes

  • track down a ton of papers from the bibliographies of Legal uncertainty in the area of genetic diagnostic testing and Genome patents and personalized medicine - what lies ahead?
    • add the above to the bibliography
  • read chapter 20, Gene patents: from discovery to invention from Gene Patents and Collaborative Licensing Models
    • add the above to the bibliography
  • read a bunch of other papers I printed

11 Jan 2010

Notes

2 Dec 2009 TODO

work completed

  • add GDx / PGx from SACGHS appendix and PGx paper to the case studies (~15?)
    • Add OTC genetic tests to the list
    • move to no.2, overall picture of kits
  • write 1 paragraph / section of paper outline
  • centralize answers to "do patents harm researchers?"
  • complete field definition - 1st draft
    • complete data, narratives, tools defn, build off of Ford report section
      • get basic market stats / picture (just GDx) - partial; just national ref labs

Duke team, Luigi interview

  • come up w/ questions
  • position on IVDMIAs
  • use interview framework from EM

Identify people to ask about IVDMIA tests

  • look at federal docket of comments in response to draft guideline
  • ask the 5 OTC companies in interview